title: Vitamin D metabolism in biliary atresia: intestinal absorptions of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3.
abstract: In children with biliary atresia, defective intestinal absorption of vitamin D and impaired hepatic uptake and 25-hydroxylation of vitamin D lead to a deficiency of vitamin D and rickets. We recently observed severe rickets in a 3-year-old boy with corrected biliary atresia resulting in jaundice, despite oral treatment with 1 alpha-hydroxyvitamin D3 (1 alpha-OHD3) or 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3]. He had low 25-hydroxyvitamin D (25-OHD) and high 1,25-(OH)2D serum levels. Intramuscular vitamin D2 administration produced radiological and biochemical evidence of recovery. Oral 1,25-(OH)2D3 (0.1 microgram/kg) and 25-OHD3 (10 micrograms/kg) tolerance tests were done to assess the ability to absorb vitamin D and the effectiveness of using these drugs orally. Eleven children with corrected biliary atresia, aged 9 months to 7 years, were studied. In oral 1,25-(OH)2D3 tolerance tests, the increments above the baseline serum levels of 1,25-(OH)2D were 140.7 +/- 27.4 pg/ml in nonjaundiced patients (n = 5). In jaundiced patients (n = 3), 1,25-(OH)2D3 absorption in two patients with high basal 1,25-(OH)2D values was lower than that of nonjaundiced patients; however, the absorption in the third patient with a low basal value was similar to that of nonjaundiced patients. In oral 25-OHD3 tolerance tests, the mean increase of serum 25-OHD was 48.9 +/- 30.6 ng/ml in nonjaundiced patients (n = 5) and 23.7 +/- 9.5 ng/ml in jaundiced patients (n = 4), the peak serum 25-OHD levels being reached 6-12 h after 25-OHD3 loading.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pediatrics, Osaka University Medical School, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kimura
authors.forename: Y
authors.initials: Y
authors.lastname: Seino
authors.forename: T
authors.initials: T
authors.lastname: Harada
authors.forename: O
authors.initials: O
authors.lastname: Nose
authors.forename: K
authors.initials: K
authors.lastname: Yamaoka
authors.forename: K
authors.initials: K
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Yabuuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Fukui
authors.forename: S
authors.initials: S
authors.lastname: Kamata
mesh_terms: D001656:Biliary Atresia / Q000150:complications / Q000378:metabolism* / Q000601:surgery; D001857:Bone Matrix / Q000378:metabolism; D002112:Calcifediol / Q000097:blood* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004872:Ergocalciferols / Q000097:blood* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D007408:Intestinal Absorption; D007565:Jaundice / Q000209:etiology; D008297:Male; D014808:Vitamin D Deficiency / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism
chemical_list: D004872:Ergocalciferols; D002112:Calcifediol